RNA:NSD-Avidity Biosciences Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 31.35

Change

-0.29 (-0.92)%

Market Cap

USD 3.88B

Volume

0.32M

Analyst Target

USD 43.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+2.91 (+0.72%)

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

-0.66 (-0.09%)

USD 84.94B
ARGX argenx NV ADR

+1.67 (+0.27%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

+0.99 (+0.41%)

USD 31.66B
BGNE BeiGene Ltd

+3.92 (+2.21%)

USD 20.24B
UTHR United Therapeutics Corporatio..

-2.78 (-0.76%)

USD 16.18B
MRNA Moderna Inc

+0.68 (+1.72%)

USD 16.10B
RPRX Royalty Pharma Plc

-0.02 (-0.08%)

USD 15.27B
SMMT Summit Therapeutics PLC

+0.33 (+1.77%)

USD 13.67B
INCY Incyte Corporation

+0.07 (+0.10%)

USD 13.52B

ETFs Containing RNA

SURI Simplify Propel Opportuni.. 3.41 % 0.00 %

+0.12 (+0.76%)

N/A
SBIO ALPS Medical Breakthrough.. 2.73 % 0.50 %

-0.04 (0.76%)

USD 0.11B
DXSP:F Xtrackers - Euro Stoxx 50.. 0.00 % 0.00 %

N/A

N/A
MOON 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 246.41% 96% N/A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 246.41% 96% N/A 97% N/A
Trailing 12 Months  
Capital Gain 234.58% 96% N/A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 234.58% 96% N/A 97% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 50.43% 78% C+ 87% B+
Dividend Return 50.43% 78% C+ 87% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 179.25% 26% F 13% F
Risk Adjusted Return 28.14% 82% B 60% D-
Market Capitalization 3.88B 93% A 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector